Išsėtinės sklerozės eigą moduliuojančio gydymo įtaka negalios progresavimui ; Disease modifying therapy and multiple sclerosis disability progression
In: Sveikatos mokslai = Health sciences, Vilnius : Sveikata, 2009, t. 19, Nr. 4(64), p. 2484-2489 ; ISSN 1392-6373, 2009, S. 2484-2489
academicJournal
Zugriff:
The accepted standard treatment of relapsing multiple sclerosis consists of medications for disease symptoms, including treatment for acute exacerbations. However, currently there is no therapy that alters the progression of physical disability related with this disease. The purpose of this study was to determine whether disease modifying treatment could slow the progressive, irreversible, neurological disability of relapsing- remitting multiple sclerosis. Mean age at the onset of disease 30 years old, duration of Multiple sclerosis disease 6 years. Relapsing multiple sclerosis were randomized into control group of 11 males and 18 females and trial group 10 males and 18 females of interferon beta-1a 44mcg s/c 3 times per week, 30 mcg interferon beta-1a i/m injection weekly, interferon beta-1b 250 μg s/c every second day, copolymero-1, glatiramer acetate 20mg s/c injections everyday. Patients of control group Multiple sclerosis onset at age 33, trial group at age 31, p> 0,05. Multiple sklerosis duration of disease 6 years in both groups, p> 0,05. Disease modifying therapies (DMT) significantly delay disability progression in relapsing (r= 0,717; p = 0,000) and remitting phase (r= 0,516; p= 0,004) on the Kurtzke Expanded Disability Status Scale (EDSS). Using methods was estimated 3,3 % for disease modifying therapies group, and 16,2 % for control group patients reached EDSS 6.0. The Kaplan Meier estimate of the proportion of patients progressing by the end of 5 years was 75% in the control group and 18% in the disease modifying therapies group p<0,05. Significant correlation among early DMT and EDSS on relapsing (0,717; p = 0,000) and remitting (r= 0,516; p= 0,004) phase, early treatment slows EDSS progression from 1.0 to 4.0 point (r= -0,542, p= 0,009, N=22)and remove the time between first and second exacerbation ( r= 0,750, p= 0,003,N= 13). [.].
Titel: |
Išsėtinės sklerozės eigą moduliuojančio gydymo įtaka negalios progresavimui ; Disease modifying therapy and multiple sclerosis disability progression
|
---|---|
Autor/in / Beteiligte Person: | Malcienė, Lina ; Straukienė, Agnė |
Link: | |
Zeitschrift: | Sveikatos mokslai = Health sciences, Vilnius : Sveikata, 2009, t. 19, Nr. 4(64), p. 2484-2489 ; ISSN 1392-6373, 2009, S. 2484-2489 |
Veröffentlichung: | 2009 |
Medientyp: | academicJournal |
Schlagwort: |
|
Sonstiges: |
|